<DOC>
	<DOCNO>NCT00657592</DOCNO>
	<brief_summary>This 12-week , double-blind , placebo-controlled study efficacy , tolerability safety oral ziprasidone monotherapy patient ( major depressive disorder ) MDD . The study involve enrollment total 120 patient MDD course 12 month across two site . Outpatients suffer MDD treat either ziprasidone placebo 12 week use sequential parallel comparison design . In light challenge major depressive disorder ( MDD ) pose clinicians patient alike , identify novel treatment urgently need help refine standard care . Judging molecular structure function , atypical neuroleptic agent offer possibility effective antidepressant . To date , several study report examine use atypical neuroleptic agent adjunctive therapy ( use along antidepressant ) MDD . These study go far suggest atypical neuroleptic agent potential treat MDD . Until , atypical neuroleptic strictly view adjunct , however , quite possible atypical neuroleptic agent may possess antidepressant property use lone therapy . The atypical neuroleptic agent ziprasidone , particular , excellent neuroleptic candidate study antipsychotic effect MDD two principal reason : structure make favorable bind neurotransmitter brain few side-effects compare drug class . This study first , double blind , placebo-controlled trial ziprasidone monotherapy MDD . If safe effective antidepressant , ziprasidone would represent additional option patient MDD . Potential subject approach regularly schedule clinic visit , upon referral another physician , response research advertisement . Interested individual opportunity review consent form family , friend , physician prior make final decision regard study enrollment . Once subject give informed consent , screen process study commence . Subjects screen visit determine eligibility . The screen visit consist medical evaluation , completion psychological rating scale , physical/neurological exam , electrocardiogram , collection blood urine . After subject pass screening , randomize one 3 study group . Subjects receive either 12 week ziprasidone , 12 week placebo , 6 week placebo follow 6 week ziprasidone . Study participants 5 8 chance receive ziprasidone point study . Subjects closely monitor study via 2 phone call weekly study coordinator . The overall safety study also well scrutinize . The investigator shall identify independent physician safety monitor , without affiliation study . He/she provide information necessary evaluate study 's safety parameter whether effective preventative measure . Various psychological assessment complete research subject every study visit . This research study design test safety and/or effectiveness investigational use drug Ziprasidone approve U.S Food Drug Administration ( FDA ) . While drug use study FDA-approved treat schizophrenia Bipolar disorder I , yet approve alleviate solely symptoms depression .</brief_summary>
	<brief_title>Treatment Major Depressive Disorder ( MDD ) With Ziprasidone</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>1 . Aged 1865 . 2 . Written informed consent . 3 . MDD , current accord fourth version Diagnostic Statistical Manual Mental Disorders ( DSMIV ) diagnose Mini International Neuropsychiatric Interview . 4 . Quick Inventory Depressive Symptomatology SelfRated score least 10 screen baseline visit . 1 . Pregnant woman . 2 . Women child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) . 3 . Treatment antidepressant 2 week prior study . 4 . Patients longer meet DSMIV criterion MDD baseline visit , patient demonstrate 25 % great reduction QIDSSR score , screen baseline . 5 . Serious suicide homicide risk , assess evaluate clinician score 4 third item HAMD . 6 . Unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease . 7 . Patients meet criterion alcohol substance dependence , active within last month . 8 . Any bipolar disorder ( current past ) . 9 . Any psychotic disorder ( current past ) . 10 . Psychotic feature current episode history psychotic feature . 11 . History seizure disorder . 12 . Clinical laboratory evidence untreated hypothyroidism . 13 . Patients require excluded medication . 14 . Prior course ziprasidone , intolerance ziprasidone dose . 15 . Any investigational psychotropic drug within last 3 month . 16 . Patients significant cardiac conduction problem screen electrocardiogram atrial fibrillation , atrial flutter , atrioventricular block , prolong abnormal QTc interval , prolong QRS interval . 17 . Patients suffer myocardial infarction within past 12 month , uncompensated heart failure , history QTc prolongation . 18 . Patients abnormal serum potassium magnesium level upon screen . 19 . Patients currently take drug prolong QTc include dofetilide , sotalol , quinidine , class Ia antiarrhythmic , class III antiarrhythmic , mesoridazine , thioridazine , chlorpromazine , droperidol , pimozide , sparfloxacin , gatifloxacin , moxifloxacin , halofantrine , mefloquine , pentamidine , arsenic trioxide , levomethadyl acetate , dolasetron methylate , probucol tacrolimus . 20 . Patients fail experience significant clinical improvement follow 3 antidepressant trial adequate duration ( least 6 week ) dose ( minimal effective dos define : fluoxetine , paroxetine , citalopram 20mg ; sertraline , fluvoxamine 50mg , escitalopram 10mg , paroxetine CR 25mg , venlafaxine 75mg , duloxetine 60mg , bupropion 150mg , 15mg mirtazapine , trazodone nefazodone 300mg ) . 21 . Patients QTc &gt; 450msec Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Depression</keyword>
	<keyword>Los Angeles</keyword>
	<keyword>Ziprasidone</keyword>
</DOC>